Changeflow GovPing Pharma & Drug Safety Novel CXC receptor ligands from GCP2
Routine Notice Added Draft

Novel CXC receptor ligands from GCP2

Favicon for changeflow.com ChangeBridge: Patent Apps - Peptides (C07K)
Published
Detected
Email

Summary

USPTO published patent application US20260092091A1 for novel polypeptide ligands of CXCR1 and/or CXCR2 derived from GCP2. The application (No. 19120219) was filed October 11, 2023, by inventors Kouvatsos, Day, Dell'Accio, and Caxaria. The invention covers polynucleotides encoding the ligands, compositions, and uses thereof.

What changed

USPTO published a patent application for novel CXC receptor ligands derived from GCP2 (Granulocyte Chemotactic Protein 2). The application claims polypeptide ligands targeting CXCR1 and CXCR2 receptors, along with encoding polynucleotides and pharmaceutical compositions. The filing (US20260092091A1) has a priority date of October 2023.

Patent applications do not create compliance obligations. For companies in pharmaceutical or biotechnology sectors, this publication establishes prior art as of the filing date. Entities developing similar CXC receptor modulators should review the claims to assess potential freedom-to-operate issues. No action is required unless the application becomes relevant to ongoing R&D programs or product development.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

CXC RECEPTOR LIGANDS

Application US20260092091A1 Kind: A1 Apr 02, 2026

Inventors

Nikolaos KOUVATSOS, Anthony DAY, Francesco DELL'ACCIO, Sara CAXARIA

Abstract

The present invention relates to novel polypeptide ligands of CXCR1 and/or CXCR2 which are derived from GCP2. The invention also concerns polynucleotides encoding the polypeptide ligands, uses of the polypeptide ligands and compositions comprising the polypeptide ligands.

CPC Classifications

C07K 14/521 A61P 19/02 A61K 38/00

Filing Date

2023-10-11

Application No.

19120219

View original document →

Get daily alerts for ChangeBridge: Patent Apps - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260092091A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent Filing Pharmaceutical Research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Research and Development
Topics
Pharmaceuticals Biotechnology

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.